E
Cellectar Biosciences, Inc. CLRB
$3.69 $0.071.93% NASDAQ
Recommendation
Prev Close
$3.62
Volume
49,221
Avg Vol (90D)
156,705
Market Cap
$15.35M
Dividend & Yield
--
52-Week Range
$2.71 - $45.90
P/E (TTM)
--
EPS (TTM)
-$10.78
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI) and Cellectar Biosciences (CLRB)
11/14/2025 - TipRanks Financial Blog
Cellectar Biosciences: Positive Outlook Amidst Challenges
11/14/2025 - TipRanks Financial Blog
Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ...
11/13/2025 - GuruFocus
Cellectar Biosciences (CLRB) Highlights Q3 2025 Progress and Future Plans
11/13/2025 - GuruFocus
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
11/13/2025 - SeekingAlpha
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
11/13/2025 - Seeking Alpha: Transcripts
Q3 2025 Cellectar Biosciences Inc Earnings Call Transcript
11/13/2025 - GuruFocus
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/13/2025 - GuruFocus
Cellectar Biosciences reports Q3 EPS ($1.41), consensus ($2.53)
11/13/2025 - The Fly
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/13/2025 - Globe Newswire
Earnings Outlook For Cellectar Biosciences
11/12/2025 - Benzinga
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on ...
11/6/2025 - GuruFocus
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
11/6/2025 - Globe Newswire
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. ...
10/27/2025 - GuruFocus
Cellectar Biosciences receives RPDD from U.S. FDA for iopofosine I 131
10/27/2025 - The Fly
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
10/27/2025 - Globe Newswire
Cellectar Biosciences files to sell 2.1M shares of common stock for holders
10/20/2025 - TipRanks Financial Blog
Cellectar Biosciences files to sell 2.1M shares of common stock for holders
10/20/2025 - The Fly
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the ...
10/14/2025 - GuruFocus
Cellectar Biosciences presents posters at AACR on CLR 121225, CLR 225
10/14/2025 - TipRanks Financial Blog
Cellectar Biosciences presents posters at AACR on CLR 121225, CLR 225
10/14/2025 - The Fly
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
10/14/2025 - Globe Newswire
Cellectar Biosciences Raises $5.8M Through Warrant Exercise
10/10/2025 - TipRanks Financial Blog
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An 'Impending' Rally
10/7/2025 - Stocktwits News Feed
Cellectar Biosciences (CLRB) Secures $5.8 Million Through Warrant Exercise
10/7/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$29.80M
EBIT (TTM)
-$30.03M
Net Income (TTM)
-$18.85M
Balance Sheet
Total Assets (Q)
$14.63M
Total Debt (Q)
$431.90K
Total Liabilities (Q)
$5.25M
Book Value Per Share (Q)
$2.34
Cash Flow
Cash from Operations (TTM)
-$29.69M
Cash from Investing (TTM)
-$61.30K
Cash from Financing (TTM)
$8.04M
Net Change in Cash (TTM)
-$21.71M
Filings
Filing Date
Thursday, November 13, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
1.24
7-Day Total Return
29.02%
30-Day Total Return
-12.35%
60-Day Total Return
-30.25%
90-Day Total Return
-26.64%
Year to Date Total Return
-62.14%
1-Year Total Return
-91.58%
2-Year Total Return
-95.08%
3-Year Total Return
-93.35%
5-Year Total Return
-99.47%
52-week Low
Nov 17, 2025 - $2.71
52-week High
Dec 03, 2024 - $45.90
Valuation
Market Cap
$15.35M - Nano Cap
Enterprise Value
$5.13M
Price/Sales (TTM)
--
Price/Book (Q)
1.55
Dividends and Shares
Shares Outstanding
3.16
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.cellectar.com
Phone Number
608 441 8120
Address
100 Campus Drive
Florham Park, NJ 07932
Country
United States
Year Founded
2002
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The... more
NASDAQ 12/03/2025 3:59PM Eastern Quotes delayed